400 - 520 West 6th Avenue
Vancouver, British Columbia
Canada V5Z 4H5
Phone: 604-879-2775

Peter B. Reiner, president and CEO
Privately Held


Active Pass Pharmaceuticals is focused on the discovery and early clinical development of novel drugs that target molecular pumps transporting molecules that regulate ATP-binding cassette transporters, or ABC transporters. ABC transporter substrates and associated diseases include the b-amyloid peptide that aggregates in the brain to cause Alzheimer’s disease; all-trans retinal, whose inefficient removal from the retina causes macular degeneration; and cholesterol, which deposits in the vasculature to cause atherosclerosis.

Active Pass has established a program in Alzheimer’s disease therapeutics based on its proprietary suite of brain-expressed ABC transporters, and is pursuing new therapeutic opportunities by employing a chemogenomic strategy.


Collaboration for ABC transporter gene expression and drug discovery: Tranzyme Inc.